Reinterventions and sac dynamics after fenestrated endovascular aortic repair with physician-modified endografts for index aneurysm repair and following proximal failure of prior endovascular aortic repair

医学 腔内修复术 外科 动脉瘤 主动脉瘤 主动脉修补术 放射科 腹主动脉瘤
作者
Andrew P. Sanders,Nicholas J. Swerdlow,Sai Divya Yadavalli,Christina L. Marcaccio,Lars Stangenberg,Marc L. Schermerhorn
出处
期刊:Journal of Vascular Surgery [Elsevier BV]
卷期号:79 (6): 1287-1294.e1 被引量:6
标识
DOI:10.1016/j.jvs.2024.01.002
摘要

Abstract

Objective

The high frequency of reinterventions after fenestrated endovascular aortic repair (FEVAR) with physician-modified endografts (PMEGs) has been well-studied. However, the impact of prior EVAR on reinterventions and sac behavior following these procedures remains unknown. We analyzed 3-year rates of reinterventions and sac dynamics following PMEG for index aneurysm repair compared with PMEG for prior EVAR with loss of proximal seal.

Methods

We performed a retrospective analysis of 122 consecutive FEVARs with PMEGs at a tertiary care center submitted to the United States Food and Drug Administration in support of an investigational device exemption trial. We excluded patients with aortic dissection (n = 5), type I to III thoracoabdominal aneurysms (n = 13), non-elective procedures (n = 4), and prior aortic surgery other than EVAR (n = 8), for a final cohort of 92 patients. Patients were divided into those who underwent PMEG for index aneurysm repair (primary FEVAR) and those who underwent PMEG for rescue of prior EVAR with loss of proximal seal (secondary FEVAR). The primary outcomes were freedom from reintervention and sac dynamics (regression as ≥5 mm decrease, expansion as ≥5 mm increase, and stability as <5 mm increase or decrease) at 3 years. Secondary outcomes were perioperative mortality and 3-year survival.

Results

Of the 92 patients included, 56 (61%) underwent primary FEVAR and 36 (39%) underwent secondary FEVAR. Secondary FEVAR patients were older (78 years [interquartile range (IQR), 74.5-83.5 years] vs 73 years [IQR, 69-78.5 years]; P < .001), more frequently male (86% vs 68%; P = .048), and had larger aneurysms (72.5 mm [IQR, 65.5-81 mm] vs 59 mm [IQR, 55-65 mm]; P < .001). Perioperative mortality was 1.8% for primary FEVAR and 2.7% for secondary FEVAR (P = .75). At 3 years, overall survival was 84% for primary FEVAR and 71% for secondary FEVAR (P = .086). Freedom-from reintervention was significantly higher for primary FEVAR than secondary FEVAR, specifically 82% vs 38% at 3 years (P < .001). Primary FEVAR also had more desirable sac dynamics relative to secondary FEVAR at 3 years (primary: 54% stable, 46% regressed, 0% expanded vs secondary: 33% stable, 28% regressed, and 39% expanded; P = .038).

Conclusions

FEVAR for primary aortic repair and FEVAR for rescue of prior EVAR with loss of proximal seal are two distinct entities. Following primary FEVAR, less than a quarter of patients have undergone reintervention at 3 years, and sac expansion was not seen in our cohort. Comparatively, 3 years after secondary FEVAR, over one-half of patients have undergone reintervention and over one-third have had ongoing sac expansion. Vigilant surveillance and a low threshold for further interventions are crucial following secondary FEVAR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
3秒前
Nalisher完成签到,获得积分10
3秒前
3秒前
苗玉完成签到,获得积分10
5秒前
7秒前
王十发布了新的文献求助10
7秒前
甜美元灵发布了新的文献求助10
9秒前
nenoaowu发布了新的文献求助10
10秒前
黑色锅包肉完成签到 ,获得积分10
11秒前
欧阳铭完成签到,获得积分10
12秒前
12秒前
13秒前
13秒前
浮游应助nenoaowu采纳,获得10
14秒前
小二郎应助nenoaowu采纳,获得10
14秒前
smile发布了新的文献求助10
14秒前
小郭完成签到 ,获得积分10
14秒前
lustr完成签到 ,获得积分10
15秒前
完美世界应助嗯嗯的嗯嗯采纳,获得10
15秒前
我是老大应助光之剑采纳,获得10
15秒前
英姑应助花见月开采纳,获得10
16秒前
16秒前
chri发布了新的文献求助10
16秒前
zoe666应助Esther采纳,获得30
18秒前
18秒前
科目三应助Hobobi采纳,获得10
19秒前
游瑞涛完成签到,获得积分10
21秒前
大蘑菇炒小蘑菇完成签到,获得积分10
21秒前
lizi发布了新的文献求助10
22秒前
jiafang完成签到,获得积分10
22秒前
23秒前
嗯嗯的嗯嗯完成签到,获得积分10
25秒前
28秒前
28秒前
29秒前
31秒前
流体离子发电机完成签到,获得积分10
31秒前
31秒前
31秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5134322
求助须知:如何正确求助?哪些是违规求助? 4335087
关于积分的说明 13505951
捐赠科研通 4172482
什么是DOI,文献DOI怎么找? 2287697
邀请新用户注册赠送积分活动 1288658
关于科研通互助平台的介绍 1229444